Press Releases April 27, 2026 07:00 PM

Qfin Holdings Filed 2025 Annual Report on Form 20-F

Qfin Holdings Files 2025 Annual Report on Form 20-F and Hong Kong Annual Report

By Ajmal Hussain
Share
Twitter Reddit Facebook LinkedIn
QFIN

Qfin Holdings, a leading AI-driven credit technology platform in China, has filed its 2025 annual report on Form 20-F with the U.S. SEC and published a corresponding report for the Hong Kong Stock Exchange. The reports include audited financial statements and reflect the company's continued efforts in leveraging AI and machine learning to enhance credit services for financial institutions, consumers, and SMEs.

Qfin Holdings Filed 2025 Annual Report on Form 20-F
QFIN
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Qfin Holdings filed its 2025 annual report on Form 20-F with the U.S. Securities and Exchange Commission and published a corresponding report for the Hong Kong Stock Exchange.
  • The company provides AI-powered credit technology services, enhancing loan lifecycle management, including borrower acquisition and credit assessment.
  • Qfin aims to make credit services more accessible and personalized for consumers and small-to-medium enterprises through advanced technology platforms.

SHANGHAI, China, April 27, 2026 (GLOBE NEWSWIRE) -- Qfin Holdings, Inc. (NASDAQ: QFIN; HKEx: 3660) (“Qfin Holdings” or the “Company”), a leading AI-empowered Credit-Tech platform in China, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2025 with the U.S. Securities and Exchange Commission on April 27, 2026. The annual report can be accessed on the Company’s investor relations website at https://ir.qfin.com as well as the SEC’s website at www.sec.gov. The Company will provide a hard copy of the annual report containing its audited consolidated financial statements, free of charge, to its shareholders and ADS holders upon request.

The Company has also published an annual report (the “Hong Kong Annual Report”) today pursuant to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“HKEx”). The Hong Kong Annual Report contains substantially the same information as set forth in the Form 20-F and can be accessed on the Company’s investor relations website at https://ir.qfin.com as well as the HKEx’s website at http://www.hkexnews.hk.

About Qfin Holdings

Qfin Holdings is a leading AI-empowered Credit-Tech platform in China. By leveraging its sophisticated machine learning models and data analytics capabilities, the Company provides a comprehensive suite of technology services to assist financial institutions and consumers and SMEs in the loan lifecycle, ranging from borrower acquisition, preliminary credit assessment, fund matching and post-facilitation services. The Company is dedicated to making credit services more accessible and personalized to consumers and SMEs through Credit-Tech services to financial institutions.

For more information, please visit: https://ir.qfin.com.

For more information, please contact:

Qfin Holdings
E-mail: [email protected]


Risks

  • The company's financial performance might be affected by regulatory uncertainties in China related to the credit technology sector, impacting fintech and financial services markets.
  • Market volatility or changing economic conditions could influence demand for credit services among consumers and SMEs, posing risks to future growth.
  • Dependence on AI and data analytics necessitates continuous investment in technology and data security, which could present operational risks if not managed properly.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026